The global giant cell arteritis market is projected to grow from USD 2.7 billion in 2026 to USD 6.0 billion by 2036, expanding at an 8.4% CAGR, according to Future Market Insights (FMI). Market growth is being supported by demand for targeted therapies, ongoing relapse management, and treatment strategies designed to reduce reliance on prolonged corticosteroid exposure.

Giant cell arteritis requires timely treatment and continued specialist monitoring because disease activity can recur and complications can affect treatment decisions. The expanding use of targeted medicines is creating additional options for steroid-sparing management, while reimbursement requirements, safety screening, and monitoring obligations continue to shape access.

Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-34738

Key Market Highlights at a Glance

The market is valued at USD 2.7 billion in 2026.
Market valuation is forecast to reach USD 6.0 billion by 2036.
The market is projected to expand at an 8.4% CAGR from 2026 to 2036.
Biologic therapies are projected to account for 49.0% of therapy-type demand in 2026.
Newly diagnosed giant cell arteritis is expected to represent 43.0% of disease-stage demand.
Injectable treatments are projected to hold 58.0% of route-of-administration demand.
Japan is projected to record an 8.6% CAGR, followed by the UK at 8.3% and the USA at 8.0%.
Targeted Therapies Support Market Expansion

Biologic therapies are projected to hold 49.0% of the market by therapy type in 2026. Their role in steroid-sparing treatment is supporting demand as clinicians consider options for patients requiring disease control alongside corticosteroid tapering.

The market is also seeing additional treatment options emerge across biologics and oral targeted therapies. Such therapies require consideration of sustained remission, safety monitoring, administration requirements, and reimbursement conditions before becoming part of routine treatment pathways.

FMI identifies the expansion of oral targeted medicines and tocilizumab biosimilars as an opportunity for broader treatment choice across relapse management, administration preferences, and country-specific access frameworks.

Newly Diagnosed Disease Represents a Major Treatment Segment

The newly diagnosed segment is projected to account for 43.0% of disease-stage demand in 2026. Initial treatment decisions can require rapid intervention, particularly when patients present with symptoms that raise concerns about vision or vascular complications.

Hospitals and specialist centers therefore require access to corticosteroid treatment, diagnostic assessment, vascular imaging, and subsequent monitoring. As patients transition into longer-term management, decisions around tapering and steroid-sparing treatment can influence medicine demand.

Injectable Treatments Remain Prominent

Injectable therapies are projected to represent 58.0% of route-of-administration demand in 2026, supported by biologic administration through subcutaneous injection and monitored infusion settings.

The expansion of biosimilar tocilizumab products is adding additional commercial options in several markets. According to FMI's analysis, competition increasingly involves differences in route availability, regional commercial access, evidence supporting treatment use, and payer requirements.

Reimbursement and Safety Requirements Create Access Challenges

Although targeted medicines expand treatment options, access can be affected by infection screening, cardiovascular assessment, reimbursement criteria, and national health technology assessments.

These considerations are particularly relevant in an older patient population where treatment decisions can involve multiple comorbidities and potential safety risks. Differences in reimbursement and specialty-pharmacy requirements can also affect how quickly eligible patients receive targeted therapies.

For manufacturers, opportunities exist in developing therapies that provide sustained remission evidence, practical dosing schedules, and data relevant to corticosteroid reduction and long-term disease management.

Regional Market Outlook

Country-level growth varies across major markets. Japan is projected to expand at an 8.6% CAGR through 2036, while the United Kingdom is expected to register an 8.3% CAGR. The United States is projected to grow at 8.0%, followed by France at 7.8% and Germany at 7.5%.

These forecasts reflect modeled market growth rather than current treatment access or patient-volume comparisons. Differences in reimbursement, specialist care infrastructure, regulatory pathways, and treatment guidelines influence country-level market development.

Analyst Perspective

“Commercial planning in giant cell arteritis must separate emergency corticosteroid use from the later steroid-sparing decision. Oral and injectable competitors need durable remission evidence that fits taper schedules and national safety and reimbursement thresholds.”

— Anurag Sharma, Principal Consultant, Future Market Insights

Competitive Landscape

Key companies profiled in the giant cell arteritis market include F. Hoffmann-La Roche Ltd., AbbVie Inc., Fresenius Kabi AG, Celltrion Inc., Organon & Co., Gedeon Richter Plc., Bio-Thera Solutions, Ltd., and Novartis AG.

Competition spans approved targeted medicines, biosimilar development, and emerging clinical programs. Recent developments include expanded availability of tocilizumab biosimilar products and continued clinical research into alternative targeted mechanisms.

Access Full Report: https://www.futuremarketinsights.com/reports/giant-cell-arteritis-market

Report Scope

Future Market Insights' Giant Cell Arteritis Market report provides analysis of market size, therapy types, disease stages, routes of administration, end users, distribution channels, regional trends, and competitive developments. The study covers the 2026–2036 forecast period across North America, Latin America, Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

The report examines markets including the United States, Japan, United Kingdom, France, Germany, and 20+ additional countries.

Related Reports:

· https://www.openpr.com/news/4633411/single-use-consumables-market-to-reach-usd-8-0-billion-by-2036-as

· https://www.openpr.com/news/4633421/surgical-dressing-material-market-to-reach-usd-19-0-billion

· https://www.openpr.com/news/4633428/electric-wheelchair-market-to-reach-usd-38-4-billion-by-2036-led

· https://www.openpr.com/news/4633454/silicone-radiopaque-vascular-ties-market-to-reach-usd-58-9

· https://www.openpr.com/news/4633468/infant-medicine-syringes-market-to-reach-usd-1-071-5-million

About Future Market Insights (FMI)

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales – [email protected]
For Media – [email protected]
For Web – https://www.futuremarketinsights.com